China SXT Pharmaceuticals Inc. [NASDAQ: SXTC] surged by $0.28 during the normal trading session on Tuesday and reaching a high of $1.28 during the day while it closed the day at $1.28. The company report on September 9, 2020 that NASDAQ Granted China SXT Pharmaceuticals, Inc. 180-Day Extension to Regain Compliance with Bid Price Requirement.
China SXT Pharmaceuticals, Inc. (NASDAQ: SXTC) (“China SXT” or the “Company”), a specialty pharmaceutical company focusing on the research, development, manufacturing, marketing, and sales of Traditional Chinese Medicine Pieces (“TCMPs”), including Advanced TCMPs (Directly-Oral TCMP and After-Soaking-Oral TCMP), fine TCMPs, regular TCMPs, and TCM Homologous Supplements (“TCMHS”) announced that on September 8, 2020, it received notification from NASDAQ granting the Company an additional 180-day period, or until March 8, 2021, to regain compliance with NASDAQ’s minimum $1.00 bid price per share requirement of Nasdaq’s Marketplace Rule 5550(a)(2) (the “Rule”).
Under NASDAQ Listing Rules, the Company was granted this extension because it met the continued listing requirement for market value of publicly held shares and all other applicable NASDAQ listing requirements, except the bid price requirement. The Company provided written notice to NASDAQ of its intention to cure the bid price deficiency during the second compliance period by affecting a reverse stock split, if necessary.
China SXT Pharmaceuticals Inc. stock has also gained 42.22% of its value over the past 7 days. However, SXTC stock has inclined by 390.80% in the 3 months of the year. Over the past six months meanwhile, it has gained 246.13% and gained 289.41% year-on date.
The market cap for SXTC stock reached $81.96 million, with 74.06 million shares outstanding and 47.40 million shares in the current float. Compared to the average trading volume of 8.13M shares, SXTC reached a trading volume of 22554410 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about China SXT Pharmaceuticals Inc. [SXTC]:
The Average True Range (ATR) for China SXT Pharmaceuticals Inc. is set at 0.12, with the Price to Sales ratio for SXTC stock in the period of the last 12 months amounting to 15.76. The Price to Book ratio for the last quarter was 3.37, with the Price to Cash per share for the same quarter was set at 0.11. Price to Free Cash Flow for SXTC in the course of the last twelve months was 102.45 with Quick ratio for the last quarter at 1.50.
SXTC stock trade performance evaluation
China SXT Pharmaceuticals Inc. [SXTC] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 42.22. With this latest performance, SXTC shares gained by 102.24% in over the last four-week period, additionally plugging by 246.13% over the last 6 months – not to mention a rise of 46.32% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SXTC stock in for the last two-week period is set at 83.15, with the RSI for the last a single of trading hit 86.84, and the three-weeks RSI is set at 80.32 for China SXT Pharmaceuticals Inc. [SXTC]. The present Moving Average for the last 50 days of trading for this stock 0.5492, while it was recorded at 1.0594 for the last single week of trading, and 0.4156 for the last 200 days.
China SXT Pharmaceuticals Inc. [SXTC]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and China SXT Pharmaceuticals Inc. [SXTC] shares currently have an operating margin of -25.98 and a Gross Margin at +52.37. China SXT Pharmaceuticals Inc.’s Net Margin is presently recorded at -199.29.
Return on Total Capital for SXTC is now -9.77, given the latest momentum, and Return on Invested Capital for the company is -100.15. Return on Equity for this stock declined to -100.32, with Return on Assets sitting at -52.53. When it comes to the capital structure of this company, China SXT Pharmaceuticals Inc. [SXTC] has a Total Debt to Total Equity ratio set at 71.52. Additionally, SXTC Total Debt to Total Capital is recorded at 41.70, with Total Debt to Total Assets ending up at 30.98. Long-Term Debt to Equity for the company is recorded at 0.39, with the Long-Term Debt to Total Capital now at 0.23.
Reflecting on the efficiency of the workforce at the company, China SXT Pharmaceuticals Inc. [SXTC] managed to generate an average of -$106,061 per employee. Receivables Turnover for the company is 0.66 with a Total Asset Turnover recorded at a value of 0.26.China SXT Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.50 and a Current Ratio set at 1.60.
China SXT Pharmaceuticals Inc. [SXTC]: Insider Ownership positions
There are presently around $1 million, or 9.00% of SXTC stock, in the hands of institutional investors. The top three institutional holders of SXTC stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 664,647, which is approximately 118.15% of the company’s market cap and around 13.70% of the total institutional ownership; GEODE CAPITAL MANAGEMENT, LLC, holding 106,568 shares of the stock with an approximate value of $0.14 million in SXTC stocks shares; and UBS GROUP AG, currently with $71000.0 in SXTC stock with ownership of nearly -59.461% of the company’s market capitalization.
6 institutional holders increased their position in China SXT Pharmaceuticals Inc. [NASDAQ:SXTC] by around 509,861 shares. Additionally, 6 investors decreased positions by around 2,756,198 shares, while 0 investors held positions by with 2,391,340 shares. The mentioned changes placed institutional holdings at 874,719 shares, according to the latest SEC report filing. SXTC stock had 4 new institutional investments in for a total of 147,388 shares, while 5 institutional investors sold positions of 2,675,257 shares during the same period.